Combination Science
Alcohol use disorder is sustained by two reinforcing systems working in parallel: the opioid-reward axis, through which alcohol triggers endogenous opioid release and downstream dopaminergic reinforcement, and the metabolic-reward axis, through which incretin signaling shapes appetite, satiety, and the salience of consummatory behavior. Single-mechanism therapies address only one of these systems at a time.
Trivalent's patent-pending combination engages both axes simultaneously. Naltrexone, a competitive mu-opioid receptor antagonist, blunts the rewarding "high" that follows a drink. Retatrutide, the first GLP-1R / GIPR / GCGR triple agonist applied to addiction medicine, modulates central reward signaling and consumption drive through a fundamentally different receptor network. Because the two agents act on non-overlapping targets, their effects on craving, consumption, and relapse are complementary rather than redundant — the foundation of a true pharmacological synergy.
The same two-brake logic carries over to opioid use disorder. There, naltrexone as a single agent has been an FDA-approved relapse-prevention therapy since 1984: it blocks exogenous opioids outright once a patient has completed medically supervised withdrawal. What it does not do is quiet the craving and cue-driven drive that survive receptor blockade — the reason so many patients discontinue. Trivalent's filed method claims pair the incretin arm with naltrexone to address that remaining half of the loop, as an adjacent and investigational indication. The 1984 approval belongs to naltrexone alone, never to the combination; there are no clinical data for the combination in any indication, and nothing here is a claim of proven efficacy.
Mu-opioid receptor antagonist
GLP-1R / GIPR / GCGR triple agonist
Two non-overlapping mechanisms, one shared reward circuit. Convergent action on distinct reward pathways yields greater-than-additive reductions in craving, consumption, and relapse than either agent achieves alone. The same two-brake reasoning is what the filed method claims extend to opioid use disorder — there as an adjacent, investigational indication, untested and unsupported by clinical data.
Synergy arises precisely because naltrexone and retatrutide intercept the drive to drink at different points in the same behavioral loop. Naltrexone diminishes the hedonic payoff of alcohol after consumption; retatrutide reduces the anticipatory salience and consummatory drive that precede it. A patient whose reward response is dampened by mu-opioid blockade and whose consumption drive is lowered by incretin modulation faces compounded resistance to the relapse cycle.
This complementarity also unlocks a dose-sparing regimen: because each agent contributes through an independent mechanism, therapeutic benefit can be achieved at sub-therapeutic doses of each component, potentially reducing the gastrointestinal burden associated with incretin agonists and the tolerability concerns associated with opioid antagonists — while preserving, or exceeding, the efficacy of either agent at full dose.
Naltrexone is a long-acting, orally bioavailable mu-opioid receptor antagonist with a well-characterized role in addiction medicine. By occupying mu-opioid receptors without activating them, it interrupts the endogenous opioid signaling that alcohol recruits, thereby dampening the dopaminergic reinforcement that makes drinking compulsive. Its effect is not on intoxication itself but on the reward learning that perpetuates the disorder.
Within Trivalent's portfolio, naltrexone is the opioid-axis arm of a deliberately bimodal strategy. Pairing it with retatrutide is intended to convert two partial, single-pathway interventions into one comprehensive, dual-pathway treatment — addressing the neurobiology of alcohol use disorder — and, investigationally, of opioid use disorder — more completely than either monotherapy.
Trivalent's patent application dedicates the majority of its independent claim families to the retatrutide + naltrexone combination — protecting the synergistic methods, the simultaneous dual-pathway mechanism, and the dose-sparing regimens that flow from it. The families below are directed to alcohol use disorder; the filings additionally include method claims applying the same combination to opioid use disorder after medically supervised withdrawal.
Each combination claim family targets a distinct, independently valuable dimension of the disorder, building defensible breadth around the retatrutide–naltrexone pairing.
Methods of treating alcohol use disorder by administering retatrutide together with naltrexone — covering co-administration, sequential administration, and a range of dosing schedules and patient comorbidities.
A method of concurrently modulating the mu-opioid pathway and the GLP-1 pathway in a single patient — the mechanistic heart of the combination, claimed independently of any particular outcome.
Methods in which the combined effect of retatrutide and naltrexone on alcohol consumption is greater than the sum of each agent administered alone.
Methods directed to a synergistic reduction in alcohol craving — pairing post-reward opioid blockade with pre-reward incretin modulation.
Methods of preventing relapse to heavy alcohol use that depend on the combined, dual-axis action of the two agents.
A method achieving therapeutic benefit using sub-therapeutic doses of retatrutide and naltrexone in combination — improving tolerability while preserving efficacy.
The retatrutide + naltrexone method claims are open to licensing in alcohol use disorder and, as an adjacent investigational indication, opioid use disorder. Partner with us to develop a dual-pathway therapy for two of medicine's most underserved indications.
Licensing Inquiries